Increased expression of TNF ligand-related molecule 1A and death receptor 3 in bladder tissues of patients with painful bladder syndrome/interstitial cystitis

ERWEI ZHANG¹, XUHUI ZHU¹, SONG HAN², ZHIFENG PENG², WEI WANG¹, JUNFA LI²* and YONG YANG¹*

¹Department of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020; ²Department of Neurobiology and Beijing Institute for Neuroscience, Capital Medical University, Beijing 100069, P.R. China

Received July 20, 2012; Accepted September 28, 2012

DOI: 10.3892/etm.2012.778

Abstract. Members of the tumor necrosis factor (TNF) superfamily have been revealed to be associated with painful bladder syndrome/interstitial cystitis (PBS/IC). TNF ligand-related molecule 1A (TL1A) and its receptor, death receptor 3 (DR3), belong to the TNF superfamily and have been implicated in chronic inflammatory diseases. Bladder biopsies from 8 female patients clinically diagnosed with PBS/IC according to the National Institute for Diabetes and Digestive and Kidney Diseases criteria and 8 female bladder carcinoma control patients were investigated to test the protein and mRNA expression levels of TL1A and DR3 using western blotting and real-time RT-PCR. The protein level ratio of TL1A to β-actin (IC, 0.65±0.03 vs. controls, 0.25±0.02, P<0.001) and of its receptor DR3 to β-actin (IC, 0.66±0.06 vs. controls, 0.27±0.02, P<0.001) were observed to be significantly higher in the patients with IC. The real-time RT-PCR ∆Cts of TL1A minus GAPDH (IC, 7.60±0.52 vs. controls, 10.08±0.32, P<0.001) and the DR3 minus GAPDH (IC, 6.68±0.60 vs. controls, 8.99±0.61, P=0.017) were observed to be significantly lower in the patients with IC, suggesting that the mRNA levels of TL1A and DR3 were higher in the PBS/IC patients. The protein and mRNA expression of TL1A and DR3 are upregulated in the bladder tissues of PBS/IC patients and may be involved in inflammation and apoptosis in PBS/IC.

Introduction

Painful bladder syndrome/interstitial cystitis (PBS/IC) is a clinical condition that mainly occurs in females. The prevalence of PBS/IC is approximately 1/1,000 (1,2). The disease presents a variety of symptoms, including urinary frequency, nocturia, pain on bladder filling and supra-pubic pain, which may ultimately limit bladder capacity. Despite investigations in the past few decades, IC remains an unresolved problem with regard to its etiology, mechanisms and clinical management.

A number of studies have demonstrated a link between PBS/IC and inflammation (3‑7). Members of the tumor necrosis factor (TNF) superfamily (TNFSF) have been revealed to be associated with PBS/IC (6,8,9). TNF ligand-related molecule 1A [TL1A; also known as vascular endothelial growth inhibitor (VEGI) and TNFSF member 15 (TNFSF15)] is an anti-angiogenic cytokine belonging to the TNFSF. TL1A regulates tumor cell behavior and is involved in chronic inflammatory disease (10‑12). These studies collectively indicate that TL1A has a role in PBS/IC.

The present study investigated the expression levels of TL1A and its receptor, death receptor 3 (DR3), in bladder biopsy tissues and revealed a potential link between TL1A, DR3 and PBS/IC.

Materials and methods

Patients and tissue samples. A total of 8 patients who fulfilled the National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK) diagnostic criteria (13) for PBS/IC and 8 age-matched hematuric controls undergoing cystoscopy for bladder carcinoma were consecutively enrolled in the present study. All participants were at least 18 years old and were enrolled in accordance with the guidelines of the Institutional Review Board of the Beijing Chaoyang Hospital (Beijing, China) and all subjects provided written informed consent.

Following evaluations of the patients through a detailed medical history analysis, physical examination and voiding diary, each patient underwent urinalysis, urine culture, urine cytology and urinary tract ultrasonography analyses. None of the patients had an intravesical treatment history due to
urinary infection and PBS/IC. All medications, including antidepressants, antihistamines and steroidal drugs, were discontinued for at least 48 h prior to hydro-distension therapy. No intravesical malignant lesions were detected during cystoscopic evaluations in which hydro-distension up to a pressure of 80 cm H$_2$O was administered for 3 min and all biopsies were obtained using the cold cut technique from an area of the posterior bladder which appeared normal after the bladder was emptied. The bladder mucosa biopsies were obtained from the same sites in the control patients with the exception of carcinomas ≥2 cm and were prepared using the same methods for comparison. A total of 4 sections of bladder tissues which were ~2×2 mm in size were obtained from each patient. Samples were stored in liquid nitrogen immediately and maintained at -80°C until used.

**Western blot analysis.** The frozen samples were rapidly thawed and homogenized at 4°C in Buffer C (50 mM Tris-HCl, pH 7.5, containing 2 mM DTT, 2 mM EDTA, 2 mM EGTA, 50 mM 4-(2-aminoethyl)-benzenesulfonylfluoride hydrochloride, 5 mg/ml each of leupeptin, aprotinin, pepstatin A and chymostatin, 50 mM KF, 50 mM okadaic acid, 5 mM sodium pyrophosphate and 2% SDS) and then sonicated to disrupt the tissues completely. Protein concentrations were measured using a BCA kit (Thermo Scientific, Pittsburgh, PA, USA).

SDS-polyacrylamide gel electrophoresis (PAGE) and western blot analysis were performed according to the laboratory's standard procedure. Firstly, 40 μg total protein from each sample was loaded onto the corresponding lane of a 10% SDS-PAGE gel. Following electrophoresis and the transfer of proteins to a polyvinylidene difluoride membrane (PVDF; GE Healthcare, Waukesha, WI, USA) at 4°C, the PVDF membrane was blocked with 10% non-fat milk in TTBS (20 mM Tris-HCl, pH 7.5, containing 0.15 M NaCl and 0.05% Tween-20) for 1 h. The blocked membrane was incubated with primary rabbit polyclonal antibody against TL1A or DR3 (1:1,000, Abcam Inc., Cambridge, UK) for 3 h. To confirm the uniform loading of the protein, the same PVDF membrane was reprobed with primary mouse monoclonal antibody against β-actin (Sigma-Aldrich Company, St. Louis, MO, USA) at a 1:2,000 dilution for 1 h. Horseradish peroxidase-conjugated goat anti-rabbit or anti-mouse IgG (ZSGB-BIO Inc., Beijing, China) were used as secondary antibodies at a 1:4,000 dilution for a 1-h incubation. An enhanced chemiluminescence (ECL) kit (Applygen Technologies Inc., Beijing, China) was used to identify the signals in the X-ray film. The order of detection of the target proteins was TL1A, DR3 and then β-actin. With each new round of detection on the same PVDF membrane, the PVDF membrane was stripped from the membrane. Protein levels of TL1A and DR3.

| Primers | Sequences (5’-3’) | Product length (bp) |
|---------|------------------|--------------------|
| GAPDH Forward | GGCAGATGCTGGCGCTGAGTA | 325 |
| GAPDH Reverse | ACAGTTTCCCCGAGGGGCCA | |
| TL1A Forward | CAAACAAAGCCAGACTCCCATCCT | 145 |
| TL1A Reverse | GAGAACATGGCTCCCCAGGTAGAT | |
| DR3 Forward | TGCCGGCGAGACAGCCCCACGAC | 66 |
| DR3 Reverse | GACGGGACGTCATCCCTCCTCAG | |

**Table I. PCR primer sequences.**

(TL1A, TNF ligand-related molecule 1A; TNF, tumor necrosis factor; DR3, death receptor 3.)

The reverse transcription reactions were performed using the High Capacity cDNA Reverse Transcription kit (GoTaq® 2-Step RT-qPCR System, Promega, Madison, WI, USA) with poly A primers. Real-time RT-PCR for each sample was performed in triplicate using the Fast Real-time PCR System STRATA MX3000 (Agilent, Boeblingen, Germany). The Ct values and the qPCR were normalized to the GAPDH housekeeping gene using the 2^(-ΔΔCt) method (14). The primers were synthesized by Taihe Gene, Inc. (Beijing, China; Table I).

**Statistical analysis.** The experimental data are expressed as the mean ± standard deviation (±s). Statistical analyses were performed using the t-test. P<0.05 was considered to indicate a statistically significant difference. Statistical analyses were performed using SPSS version 17.0 (SPSS, Inc., Chicago, IL, USA).

**Results**

**Description of patients.** The clinical characteristics of the 8 IC and 8 control patients are shown in Table II. All patients were female and all subjects who had suffered from an acute bacterial infection within 3 months were excluded. None of the control patients exhibited any symptoms related to IC and biopsy samples were obtained ≥2 cm from the bladder tumor margins. All but 1 of the subjects were postmenopausal. No common medical history was identified among the patients.

**Protein levels of TL1A and DR3.** The TL1A and DR3 protein expression levels were observed to be increased in the bladder biopsies of the patients with IC compared with those of the controls using western blotting. The TL1A to β-actin ratio in the IC patients was 0.65±0.03 and that in the control group was 0.25±0.02 which was statistically significantly different (P<0.001). The TL1A protein levels of the IC patients were
2.6 fold higher than those of the controls. The DR3 to β-actin ratio in the IC patients was 0.66±0.06 and that in the controls was 0.27±0.02 which was statistically significantly different (P<0.001). The DR3 protein levels of the IC patients were 2.44 fold higher than those of the controls (Fig. 1).

mRNA expression levels of TL1A and DR3.
The TL1A and DR3 mRNA expression levels were also evaluated in the bladder biopsies using real-time RT-PCR. The ΔCts of TL1A minus GAPDH in the patient and control groups were 7.60±0.52 and 10.08±0.32, respectively, and were statistically significantly different (P<0.001). The TL1A mRNA levels of the patients were upregulated 5.28-fold. The ΔCts of DR3 minus GAPDH in the patient and control groups were 6.68±0.60 and 8.99±0.61, respectively, which was statistically significantly different (P=0.017). The DR3 mRNA levels of the patients were upregulated 4.92-fold (Fig. 2).

Discussion
PBS/IC is a clinical condition that manifests mainly as storage period symptoms, including frequency and supra-pubic pain, suggesting a mainly sensation-based problem. In the present study, patients with PBS/IC were revealed to have elevated levels of the proteins and mRNA of TL1A and DR3. TL1A is a cytokine belonging to the TNFSF. Three isoforms of TNFSF15 have been reported; TL1A is the most predominant of these isoforms and may be active in inflammation and apoptosis. TL1A has been demonstrated to be significant in tumor cell behavior and chronic inflammatory disease (10,11,15). DR3 is the receptor for TL1A and TNF-related weak inducer of apoptosis (TWEAK). After binding to its ligand, DR3 binds to the adaptor molecule TNF-related apoptosis death domain (TRADD) through its cytoplasmic death domain. TRADD recruitment causes downstream molecules to activate NF-κB and mitogen-activated protein kinase (MAPK) signaling or triggers caspase activation and programmed cell death under certain conditions (16).

Although the results of the present study suggest an upregulation of TL1A and DR3 in PBS/IC patients, their precise role in this disease was not addressed. However, the known functions of TL1A indicate that it is likely to be involved in the pathogenesis of PBS/IC. Firstly, TL1A is active in inflammation and apoptosis (17-19). The activation of NF-κB in the bladder biopsies of PBS/IC patients (predominantly in the cells of the urothelium and submucosal layer) and apoptosis of endothelial cells in this condition have been reported (20-23). There is also evidence that apoptosis in PBS/IC is mediated by...
inflammation (23). Uprogulation of TL1A and its receptor may trigger inflammation and apoptosis in the bladder, in particular in the elderly population (24). With regard to the evidence that TNF-related apoptosis-inducing ligand and TNFSF14 are also important in PBS/IC (6,8), it may be suggested that TL1A and DR3 elevation is one of the factors contributing to the inflammation and apoptosis in PBS/IC. Secondly, TL1A has been shown to have an anti-angiogenic function (25,26). Uprogulation of TL1A and DR3 may inhibit angiogenesis which then causes bladder ischemia and destroys the blood-urine barrier. Previous studies have demonstrated that there is ischemia in PBS/IC patient bladders (27) and impairment of the bladder surface in the PBS/IC condition (22,28). The clinical identification of glomerular bleeding is the only non-exclusive diagnostic evidence of PBS/IC according to the NIDDK criteria. The underlying cause of glomerular bleeding may be the abnormality of the blood vessels arising as a result of this mechanism. Steroid hormone treatments are capable of alleviating the symptoms, which provides supporting evidence for this hypothesis since these drugs inhibit inflammation (29).

The present study has limitations, primarily due to the limited number of patients. The mechanism should be further tested in in vivo models. However, there are no widely recognized animal models in which to test this hypothesis. At present, we aim to conduct a larger scale clinical investigation and possibly to specifically block this signaling pathway in a suitable IC disease model, in order to elucidate the precise roles of TL1A and DR3 in PBS/IC. The promising results of the present study justify a larger population study and further mechanistic studies to identify the precise pathogenic role of TL1A and DR3 in PBS/IC and to explore their potential as a possible therapeutic approach.

In conclusion, the present study revealed that TL1A and its receptor DR3 were upregulated in patients with PBS/IC. Therefore, TL1A, a cytokine which triggers NF-κB activation, induces apoptosis and inhibits vascular formation via its receptor DR3, may be important in the pathogenesis of PBS/IC.

Acknowledgements

This study was financially supported by the National Natural Science Foundation of China (no. 81070603). The authors appreciate the valuable comments from the other members of their laboratories.

References

1. Clemens JQ, Meenan RT, Rossetti MC, Gao SY and Calhoun EA: Prevalence and incidence of interstitial cystitis in a managed care population. J Urol 173: 98-102, 2005.
2. Choe JH, Son H, Song YS, Kim JC, Lee JZ and Lee KS: Prevalence of painful bladder syndrome/interstitial cystitis-like symptoms in women: A population-based study in Korea. World J Urol 29: 103-108, 2011.
3. Wang ZY and Bjorling DE: CXCL10 peptide in bladder urothelium and urine as possible biomarkers for diagnosis of ulcerative interstitial cystitis. Eur Urol Suppl 9: 212, 2010.
4. Richter B, Roslin A, Hesse U, Nordling J, Johansen JS, Horn T and Hansen AB: YKL-40 and mast cells are associated with detrusor fibrosis in patients diagnosed with bladder pain syndrome/interstitial cystitis according to the 2008 criteria of the European Society for the Study of Interstitial Cystitis. Histopathology 57: 371-383, 2010.
5. Ogawa T, Homma T, Iwagawa K, Seki S, Ishizuka O, Imamura T, Akahane S, Homma Y and Nishizawa O: CXCR3 binding chemokine and TNFSF14 over expression in bladder urothelium of patients with ulcerative interstitial cystitis. J Urol 183: 1206-1212, 2010.
6. Lv J, Luo Y, Leng J, Xue W, Liu D and Huang Y: aberrant expression of monocyte chemottractant protein-1 (mcp-1) in interstitial cystitis patients. Sci Res Essays 5: 663-667, 2010.
7. Keros O, Akkaya E, Koksal JT, Bassioung IC, Ciftcioglu MA, Sanlioglu S and Kukel E: Importance of TNF-related apoptosis-inducing ligand in pathogenesis of interstitial cystitis. Int Urol Nephrol 42: 393-399, 2010.
8. Chen MC, Keshavan P, Gregory KD and Klump DJ: RANTES mediates TNF-dependent lamina propria mast cell accumulation and barrier dysfunction in neurogenic cystitis. Am J Physiol Renal Physiol 292: F1372-F1379, 2007.
9. Zhang N, Sanders AJ, Ye L, Kynaston HG and Jiang WG: Expression of vascular endothelial growth inhibitor (VEGI) in human urothelial cancer of the bladder and its effects on the adhesion and migration of bladder cancer cells in vitro. Anticancer Res 30: 87-95, 2010.
10. Song YJ, Meylan F, Botson J, Goldbach-Mansky R, Lee D and Siegel R: TL1A-DR3 interactions are important in both adaptive and innate immunity in inflammatory arthritis. Clin Immunol 135: S88, 2010.
11. Tan KB, Harrop J, Reddy M, Young P, Terrett J, Emery J, Moore G and Truneh A: Characterization of a novel TNF-like ligand and recently described TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells. Gene 204: 35-46, 1997.
12. Gillenwater JY and Wein AJ: Summary of the National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases Workshop on Interstitial Cystitis, National Institutes of Health, Bethesda, Maryland, August 28-29, 1987. J Urol 140: 203-206, 1988.
13. Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3: 1101-1108, 2008.
14. Taraban YV, Slibioda TJ, Willoughby JE, Buchanan SL, James S, Sheth B, Smyth NR, Thomas GJ, Wang EC and Al-Shamkhani A: Sustained TL1A expression modulates effector and regulatory T-cell responses and drives intestinal goblet cell hyperplasia. Mucosal Immunol 4: 186-196, 2011.
15. Pobeznitskaya YL, Choksi S, Morgan MJ, Cao X and Liu ZG: The adaptor protein TRADD is essential for TNF-like ligand 1/death receptor 3 signaling. J Immunol 186: 5212-5216, 2011.
16. Kang YJ, Kim WJ, Bae HU, Kim DJ, Park YB, Park JE, Kwon KO, Kim YS and Lee WH: Involvement of TL1A and DR3 in induction of pro-inflammatory cytokines and matrix metalloproteinase-9 in atherogenesis. Cytokine 29: 229-235, 2005.
17. Young HA and Tovey MG: TL1A: a mediator of gut inflammation. Proc Natl Acad Sci USA 103: 8303-8304, 2006.
18. Altamirano CV, Pang S, Li LY and Berenson JR: Vascular endothelial growth inhibitor (vegi) inhibits the growth of multiple tumor xenografts and recently described TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells. Gene 36: 32-41, 2008.
25. Wang L, Pan W, Zhu FL, Jiao BH, Lou YH, Xiao Y and Qi ZT: Cloning, expression and biological activity of VEGI(151), a novel vascular endothelial cell growth inhibitor. Acta Biochimica Et Biophysica Sinica 32: 485-489, 2000.

26. Chen X, Wu JH, Liu HN, He Z, Gu M, Wang N, Ma J, Hu J, Xia L, He H, Yuan J, Li J, Li L, Li M and Zhu X: Approaches to efficient production of recombinant angiogenesis inhibitor rhVEGI-192 and characterization of its structure and antiangiogenic function. Protein Sci 19: 449-457, 2010.

27. Pontari MA, Hanno PM and Ruggieri MR: Comparison of bladder blood flow in patients with and without interstitial cystitis. J Urol 162: 330-334, 1999.

28. Altuntas CZ, Daneshgari F, Sakalar C, Goksoy E, Gulen MF, Kavran M, Qin J, Li X and Tuohy VK: Autoimmunity to uroplakin II causes cystitis in mice: a novel model of interstitial cystitis. Eur Urol 61: 193-200, 2012.

29. Hanno PM, Burks DA, Clemens JQ, Dmochowski RR, Erickson D, Fitzgerald MP, Forrest JB, Gordon B, Gray M, Mayer RD, Newman D, Nyberg L Jr, Payne CK, Wesselmann U and Faraday MM; Interstitial Cystitis Guidelines Panel of the American Urological Association Education and Research, Inc.: AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol 185: 2162-2170, 2011.